Research across Kidney Diseases
Related studies from across the Kidney Diseases family.
Part of Kidney Diseases
1 published article · Updated continuously
10 trials tracked for Autosomal dominant polycystic kidney disease: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 619 citations.
Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Tolvaptan treatment is associated with significant changes in kidney volume and clinical progression markers in patients with ADPKD. Specifically, Tolvaptan was shown to result in a significantly higher percentage change per year in total kidney volume (TKV) compared to placebo (2.777% vs 5.608%, p<0.0001) 3. Additionally, Tolvaptan treatment resulted in a significantly greater number of clinical progression events per 100 follow-up years compared to placebo (43.94 vs 50.04, p=0.0095) 3.
Tolvaptan administration has been associated with faster declines in renal function and changes in kidney size. Studies demonstrated a significantly greater annual decrease in renal function per year for Tolvaptan compared to placebo (-2.555 vs -3.682, p<0.0001) 3. Furthermore, Tolvaptan MR was associated with significant reductions in total kidney volume (TKV) at both week 3 and week 8 7.
Tolvaptan treatment has been shown to impact patient-reported outcomes and physiological markers. Patients treated with Tolvaptan MR showed a statistically significant improvement in the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS) 7. Additionally, Tolvaptan was associated with significant changes in measured glomerular filtration rate (mGFR) after 3 weeks of treatment 10, while effects on effective renal plasma flow (ERPF) and filtration fraction were not statistically significant 10.
AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Kidney Diseases family.